Overexpression of EZH2 has been reported in several human malignancies, leading to EZH2 dysfunction and the suppression of tumor suppressor gene expression in conditions such as prostate cancer, NK/T-cell lymphoma, and melanoma [12–14]. This evidence concerns the gene EZH2 and neoplasm.